Knight Therapeutics, a specialty pharmaceutical company, completed the acquisition of a 51% stake in Grupo Biotoscana, a Brazilian pharmaceutical company, from Advent and Essex Woodland for $144m. The price implies a 22.2% premium to GBT’s 30-day volume weighted average share price as of October 18, 2019. “We are happy to welcome the GBT team into the Knight family and are excited to begin working with them to become the partner of choice for biotech and pharmaceutical companies looking for a pan-American (ex-US) one-stop commercial solution,” Samira Sakhia, Knight President.